Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06511141 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 2 entries
    • Eligibility criteria expanded, about 14 words
    • Secondary endpoints: details revised at 1 of 1 entry
  2. Study sites: 22 to 23v21
  3. Study sites: 21 to 22v20
  4. Study sites: 20 to 21v19
  5. Re-verified, no change to tracked fieldsv18
  6. Site details revised at 2 of 20 sitesv17
  7. Study completion pushed from Mar 2028 to Dec 2028
    • Study sites: 19 to 20
    v16
  8. Study sites: 13 to 19v15
  9. Eligibility criteria expanded, about 3 wordsv14
  10. 2 versions Re-verified since Dec 1, 2025, no change to tracked fieldsv12-v13
  11. Site details revised at 2 of 13 sitesv11
  12. Study sites: 12 to 13v10
  13. Primary completion date: Oct 2027 to Dec 2027
    • Study completion date: Dec 2027 to Mar 2028
    • Eligibility criteria expanded, about 3 words
    v9
  14. Study sites: 11 to 12v8
  15. Primary completion date: Mar 2026 to Oct 2027v7 Show 7 more changesShow less
    • Primary endpoints: 3 to 2
    • Study sites: 9 to 11
    • Study completion date: Mar 2027 to Dec 2027
    • Start date: Oct 1, 2024 to Oct 22, 2024
    • Eligibility criteria shortened, about 38 words
    • Secondary endpoints expanded, about 8 words
    • Study arms: 1 to 3
  16. Study sites: 6 to 9v6
  17. Enrollment target: 120 to 150
    • Study sites: 4 to 6
    • Primary completion date: Dec 2026 to Mar 2026
    v5
  18. Study sites: 1 to 4v4
  19. Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Jun 2026 to Dec 2026
    • Study completion date: Dec 2026 to Mar 2027
    • Start date changed from estimate of Aug 2024 to Oct 1, 2024
    • Study description expanded, about 46 words
  20. Start date: Jul 2024 to Aug 2024v2
  21. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Axonics, Inc.
5 trials monitored
See 1 trial at risk
Prostate Cancer
2,546 trials monitored
See 172 trials at risk
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Trial Details
NCT Number NCT06511141
Lead Sponsor Axonics, Inc.
Conditions
(from sponsor)		 Overactive Bladder, Urinary Urgency Incontinence, Benign Prostatic Hyperplasia, Prostate Cancer, Prostatectomy, Urinary Frequency
Related terms Prostatic Hyperplasia, Prostatic Neoplasms, Urinary Bladder, Overactive
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov